|
English
|
正體中文
|
简体中文
|
總筆數 :2854334
|
|
造訪人次 :
53356137
線上人數 :
339
教育部委託研究計畫 計畫執行:國立臺灣大學圖書館
|
|
|
顯示項目 712446-712455 / 2348971 (共234898頁)
<< < 71240 71241 71242 71243 71244 71245 71246 71247 71248 71249 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2020-08-02 |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen, TY;Winkelman, JW;Mao, WC;Tzeng, NS;Kuo, TBJ;Yang, CCH;Tsai, HJ;Wu, CS |
| 臺大學術典藏 |
2018-09-10T18:06:04Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang, S.-K. and Hsieh, M.-S. and Lee, M.-R. and Keng, L.-T. and Ko, J.-C. and Shih, J.-Y.; MENG-RUI LEE; KENG LI-TA; JEN-CHUNG KO; SHENG-KAI LIANG; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Min-Shu Hsieh;Lee M.-R.;Keng L.-T.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; MIN-SHU HSIEH; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:37Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Ko J.-C.;Jin-Yuan Shih; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T05:56:07Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
顯示項目 712446-712455 / 2348971 (共234898頁)
<< < 71240 71241 71242 71243 71244 71245 71246 71247 71248 71249 > >>
每頁顯示[10|25|50]項目
|
